Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
- Conditions
- First Posted Date
- 2003-04-29
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005836
- Locations
- 🇺🇸
Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States
🇺🇸Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
- Conditions
- First Posted Date
- 2003-04-21
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00005839
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Beckman Research Institute, City of Hope, Los Angeles, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-04-21
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00004220
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
- Conditions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Albany Medical College
- Registration Number
- NCT00004257
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
- Conditions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00004243
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Beckman Research Institute, City of Hope, Los Angeles, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2011-09-21
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00058149
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1608
- Registration Number
- NCT00058474
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00057863
- Locations
- 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2012-07-04
- Target Recruit Count
- 16
- Registration Number
- NCT00055822
- Locations
- 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 73
- Registration Number
- NCT00056030
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.